Bibliography
- Callis TE, Jensen BC, Weck KE, Willis MS. Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Rev Mol Diagn 2010;10(3):329-51
- Rodriguez JE, McCudden CR, Willis MS. Familial hypertrophic cardiomyopathy: basic concepts and future molecular diagnostics. Clin Biochem 2009:42(9):755-65
- Maron BJ, Gardin JM, Flack JM, Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (Young) adults. Circulation 1995;92(4):785-9
- Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 2008;5(3):158-68
- Girolami F, Ho CY, Semsarian C, Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 2010;55(14):1444-53
- Hershberger RE, Lindenfeld J, Mestroni L, Genetic evaluation of cardiomyopathy – a Heart Failure Society of America practice guideline. J Card Fail 2009;15(2):83-97
- Teekakirikul P, Eminaga S, Toka O, Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest 2010;120(10):3520-9
- Ho CY, Lopez B, Coelho-Filho OR, Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363(6):552-63
- Wang L, Seidman JG, Seidman CE. Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med 2010;152(8):513-20, W181
- Maron BJ, Towbin JA, Thiene G, Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113(14):1807-16
- Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 2010;12(11):655-67
- Bai R, Napolitano C, Bloise R, Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol 2009;2(1):6-15
- Napolitano C, Priori SG, Schwartz PJ, Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 2005;294(23):2975-80
- Tester DJ, Benton AJ, Train L, Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing. Am J Cardiol 2010;106(8):1124-8
- Summers KM, Bokil NJ, Lu FT, Mutations at KCNQ1 and an unknown locus cause long QT syndrome in a large Australian family: implications for genetic testing. Am J Med Genet A 2010;152A(3):613-21
- Schwartz PJ, Priori SG, Napolitano C. How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. J Cardiovasc Electrophysiol 2003;14(10):1120-1
- Westenskow P, Splawski I, Timothy KW, Compound mutations: a common cause of severe long-QT syndrome. Circulation 2004;109(15):1834-41
- Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005;2(5):507-17
- Wainscoat JS, Kanavakis E, Wood WG, Thalassaemia intermedia in Cyprus: the interaction of alpha and beta thalassaemia. Br J Haematol 1983;53(3):411-16
- MacRae CA. Closer look at genetic testing in long-QT syndrome: will DNA diagnostics ever be enough? Circulation 2009;120(18):1745-8
- Moss AJ, Greenberg H, Case RB, Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110(25):3760-5
- Bardy GH, Lee KL, Mark DB, Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352(3):225-37
- Meune C, Van Berlo JH, Anselme F, Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 2006;354(2):209-10
- Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. J Am Coll Cardiol 2004;43(7):1137-44